PHLDA2 and breast cancer: When using the optimal cutoff to separate BC patients and controls into hypomethylated and hypermethylated groups (Table S11), differentially methylated CpG sites in the target regions of KCNQ1OT1 and PHLDA2 were still associated with the risk of BC (Table S12).